| RESEARCH ARTICLE
|Year : 2014 | Volume
| Issue : 1 | Page : 105-108
Comparision of uroprotective activity of reduced glutathione with Mesna in Ifosfamide induced hemorrhagic cystitis in rats
Syed Amir Ali1, Sandeep Kumar Danda2, Syed Abdul Azeez Basha1, Asif Rasheed1, Osman Ahmed1, M Muqtedar Ahmed1
1 Deccan School of Pharmacy, Hyderabad, Andhra Pradesh, India
2 Bharat Institute of Technology, Hyderabad, Andhra Pradesh, India
Background: Ifosfamide (IFO) is widely used DNA-alkylating agents in cancer chemotherapy for management of solid tumors and hematological malignancies. However, hemorrhagic cystitis limits the use of IFO.
Objectives: To compare the efficiency of reduced glutathione with 2-Mesna in reducing Ifosfamide (IFO) induced hemorrhagic cystitis (HC) in wistar rats.
Materials and Methods: Ifosfamide and 2-Mesna were dissolved in sterile water for injection and administered to wistar rats of albino strains. The rats were randomly assigned to one of the four groups of 6 rats each: Group I: Vehicle control; Group II: 120 mg/kg of IFO alone by intraperitoneal injection (i.p); Group III: 40 mg/kg Mesna i.p., at the same time and at 4 and 8 h after IFO administration; Group IV: 500 mg/kg of glutathione i.p., 30 min prior to IFO as above. The animals were observed for 5 days. On 6 th day, rats were sacrificed by dissecting the intrajugular vein. The bladders were macroscopically and histopathologically evaluated.
Results: Control animals had normal bladders with assigned scores of '0' for the three parameters of edema, hemorrhage and histopathological changes. All the animals receiving IFO (group II) had evidence of HC as evidenced by alterations of edema and hemorrhages. These alterations were almost abolished (P < 0.001) by the glutathione (group III) or Mesna (group IV) in IFO-treated animals.
Conclusion: Glutathione could be as useful as Mesna in the preventive management of IFO-induced HC.
Syed Amir Ali
Deccan School of Pharmacy, Hyderabad, Andhra Pradesh
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*